Pfizer drops preclinical biosimilar programs

Pfizer Inc. (NYSE:PFE) will cease development of its five preclinical biosimilar programs; the discontinued programs are undisclosed. Pfizer spokesperson Thomas Biegi said the decision, which was based on the pharma's annual R&D investment review, is limited to the preclinical assets only. Pfizer has three marketed biosimilars and five biosimilars in mid- to late-state clinical development. Biegi said the pharma will continue to monitor biosimilar opportunities during regular portfolio evaluations...